Cargando…

Multi-source financing for tuberculosis treatment in China: key issues and challenges

BACKGROUND: The End Tuberculosis (TB) Strategy of the World Health Organization highlights the need for patient-centered care and social protection measures that alleviate the financial hardships faced by many TB patients. In China, TB treatments are paid for by earmarked government funds, social he...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Qian, Jiang, Wei-Xi, Zhang, Hui, Cheng, Jun, Tang, Sheng-Lan, Wang, Wei-Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943260/
https://www.ncbi.nlm.nih.gov/pubmed/33750460
http://dx.doi.org/10.1186/s40249-021-00809-4
_version_ 1783662451508641792
author Long, Qian
Jiang, Wei-Xi
Zhang, Hui
Cheng, Jun
Tang, Sheng-Lan
Wang, Wei-Bing
author_facet Long, Qian
Jiang, Wei-Xi
Zhang, Hui
Cheng, Jun
Tang, Sheng-Lan
Wang, Wei-Bing
author_sort Long, Qian
collection PubMed
description BACKGROUND: The End Tuberculosis (TB) Strategy of the World Health Organization highlights the need for patient-centered care and social protection measures that alleviate the financial hardships faced by many TB patients. In China, TB treatments are paid for by earmarked government funds, social health insurance, medical assistance for the poor, and out-of-pocket payments from patients. As part of Phase III of the China-Gates TB project, this paper introduces multi-source financing of TB treatment in the three provinces of China and analyzes the challenges of moving towards universal coverage and its implications of multi-sectoral engagement for TB care. MAIN TEXT: The new financing policies for TB treatment in the three provinces include increased reimbursement for TB outpatient care, linkage of TB treatment with local poverty alleviation programs, and use of local government funds to cover some costs to reduce out-of-pocket expenses. However, there are several challenges in reducing the financial burdens faced by TB patients. First, medical costs must be contained by reducing the profit-maximizing behaviors of hospitals. Second, treatment for TB and multi-drug resistant TB (MDR-TB) is only available at county hospitals and city or provincial hospitals, respectively, and these hospitals have low reimbursement rates and high co-payments. Third, many patients with TB and MDR-TB are at the edge of poverty, and therefore ineligible for medical assistance, which targets extremely poor individuals. In addition, the local governments of less developed provinces often face fiscal difficulties, making it challenging to use of local government funds to provide financial support for TB patients. We suggest that stakeholders at multiple sectors should engage in transparent and responsive communications, coordinate policy developments, and integrate resources to improve the integration of social protection schemes. CONCLUSIONS: The Chinese government is examining the establishment of multi-source financing for TB treatment by mobilization of funds from the government and social protection schemes. These efforts require strengthening the cooperation of multiple sectors and improving the accountability of different government agencies. All key stakeholders must take concrete actions in the near future to assure significant progress toward the goal of alleviating the financial burden faced by TB and MDR-TB patients. GRAPHIC ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-7943260
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79432602021-03-10 Multi-source financing for tuberculosis treatment in China: key issues and challenges Long, Qian Jiang, Wei-Xi Zhang, Hui Cheng, Jun Tang, Sheng-Lan Wang, Wei-Bing Infect Dis Poverty Opinion BACKGROUND: The End Tuberculosis (TB) Strategy of the World Health Organization highlights the need for patient-centered care and social protection measures that alleviate the financial hardships faced by many TB patients. In China, TB treatments are paid for by earmarked government funds, social health insurance, medical assistance for the poor, and out-of-pocket payments from patients. As part of Phase III of the China-Gates TB project, this paper introduces multi-source financing of TB treatment in the three provinces of China and analyzes the challenges of moving towards universal coverage and its implications of multi-sectoral engagement for TB care. MAIN TEXT: The new financing policies for TB treatment in the three provinces include increased reimbursement for TB outpatient care, linkage of TB treatment with local poverty alleviation programs, and use of local government funds to cover some costs to reduce out-of-pocket expenses. However, there are several challenges in reducing the financial burdens faced by TB patients. First, medical costs must be contained by reducing the profit-maximizing behaviors of hospitals. Second, treatment for TB and multi-drug resistant TB (MDR-TB) is only available at county hospitals and city or provincial hospitals, respectively, and these hospitals have low reimbursement rates and high co-payments. Third, many patients with TB and MDR-TB are at the edge of poverty, and therefore ineligible for medical assistance, which targets extremely poor individuals. In addition, the local governments of less developed provinces often face fiscal difficulties, making it challenging to use of local government funds to provide financial support for TB patients. We suggest that stakeholders at multiple sectors should engage in transparent and responsive communications, coordinate policy developments, and integrate resources to improve the integration of social protection schemes. CONCLUSIONS: The Chinese government is examining the establishment of multi-source financing for TB treatment by mobilization of funds from the government and social protection schemes. These efforts require strengthening the cooperation of multiple sectors and improving the accountability of different government agencies. All key stakeholders must take concrete actions in the near future to assure significant progress toward the goal of alleviating the financial burden faced by TB and MDR-TB patients. GRAPHIC ABSTRACT: [Image: see text] BioMed Central 2021-03-10 /pmc/articles/PMC7943260/ /pubmed/33750460 http://dx.doi.org/10.1186/s40249-021-00809-4 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Opinion
Long, Qian
Jiang, Wei-Xi
Zhang, Hui
Cheng, Jun
Tang, Sheng-Lan
Wang, Wei-Bing
Multi-source financing for tuberculosis treatment in China: key issues and challenges
title Multi-source financing for tuberculosis treatment in China: key issues and challenges
title_full Multi-source financing for tuberculosis treatment in China: key issues and challenges
title_fullStr Multi-source financing for tuberculosis treatment in China: key issues and challenges
title_full_unstemmed Multi-source financing for tuberculosis treatment in China: key issues and challenges
title_short Multi-source financing for tuberculosis treatment in China: key issues and challenges
title_sort multi-source financing for tuberculosis treatment in china: key issues and challenges
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943260/
https://www.ncbi.nlm.nih.gov/pubmed/33750460
http://dx.doi.org/10.1186/s40249-021-00809-4
work_keys_str_mv AT longqian multisourcefinancingfortuberculosistreatmentinchinakeyissuesandchallenges
AT jiangweixi multisourcefinancingfortuberculosistreatmentinchinakeyissuesandchallenges
AT zhanghui multisourcefinancingfortuberculosistreatmentinchinakeyissuesandchallenges
AT chengjun multisourcefinancingfortuberculosistreatmentinchinakeyissuesandchallenges
AT tangshenglan multisourcefinancingfortuberculosistreatmentinchinakeyissuesandchallenges
AT wangweibing multisourcefinancingfortuberculosistreatmentinchinakeyissuesandchallenges